Sesen Bio, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 1
- Market Cap
- -
- Website
- https://sesenbio.com
Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG
- Conditions
- Bladder Cancer
- Interventions
- Biological: Vicinium
- First Posted Date
- 2015-05-20
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Sesen Bio, Inc.
- Target Recruit Count
- 133
- Registration Number
- NCT02449239
Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin
- First Posted Date
- 2007-06-04
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- Sesen Bio, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT00481936
- Locations
- 🇬🇪
Chemotherapy and Immunotherapy clinic Medulla, Tbilisi, Georgia
🇷🇺Yaroslavl Regional Clinical Oncology Hospital, Yaroslavl, Russian Federation
🇷🇺Blokhin Cancer Research Centre, Department of Clinical Pharmacology and Chemotherapy, Moscow, Russian Federation
Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ
- Conditions
- Bladder CancerBladder TumorsUrinary Bladder CancerBladder Neoplasms
- Interventions
- First Posted Date
- 2007-04-19
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Sesen Bio, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT00462488
- Locations
- 🇨🇦
The Male/Female Health and Research Centre, Royal Court Medical Centre, Barrie, Ontario, Canada
🇺🇸Urology of Virginia, Newport News, Virginia, United States
🇺🇸Southeastern Research Group, Inc., Tallahassee, Florida, United States
Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer
- Conditions
- Neoplasms, Squamous CellCarcinoma, Squamous CellCarcinoma, Squamous Cell of Head and NeckHead and Neck NeoplasmsHead and Neck CancerMouth Neoplasms
- Interventions
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2015-12-23
- Lead Sponsor
- Sesen Bio, Inc.
- Target Recruit Count
- 165
- Registration Number
- NCT00412776
- Locations
- 🇪🇸
Hospital 12 de Octubre, Madrid, Spain
🇦🇷Centro de Estudio y Tratamiento de las Enfermedades Neoplasicas (CETEN), Buenos Aires, Argentina
🇦🇷Hospital de Clinicas "Jose de San Martin", Buenos Aires, Argentina
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
- Conditions
- Squamous Cell Carcinoma of the Head and NeckHead and Neck CancerCarcinoma, Squamous CellMouth NeoplasmsNeoplasms, Squamous CellHead and Neck Neoplasms
- Interventions
- First Posted Date
- 2006-01-04
- Last Posted Date
- 2015-12-23
- Lead Sponsor
- Sesen Bio, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT00272181
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇨🇦CHUQ, L'Hotel-Dieu de Quebec, Quebec City, Quebec, Canada
🇺🇸Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States